| Detected | Trial | Change |
|---|---|---|
| 2026-07-31 | NCT07659782 A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer |
Recruitment opened |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-08-05 | NCT07747506 Continued Access to Avutometinib in Combination With Defactinib in Patients With… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06072781 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous… | Low Grade Serous Ovarian Cancer | Recruiting |
| Phase 2 | |||
| NCT07659782 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Recruiting |
| NCT07659795 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | Colorectal Cancer | Recruiting |
| NCT07644559 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting |
| NCT04625270 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent… | Low Grade Ovarian Serous Adenocarcinoma | Active, Not Recruiting |
| NCT06682572 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in… | Low Grade Serous Ovarian Cancer | Active, Not Recruiting |
| NCT07747506 | Continued Access to Avutometinib in Combination With Defactinib in Patients With… | Low Grade Ovarian Serous Adenocarcinoma | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Pancreatic Ductal Adenocarcinoma | Recruiting |
| NCT05669482 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in… | KRAS Activating Mutation | Active, Not Recruiting |
| NCT05074810 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS… | Non Small Cell Lung Cancer | Active, Not Recruiting |